ArticleCancer research2012
A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy.
Article in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 96 citations in OpenAlex.
- A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer.Clinical breast cancer · 2021Trial
- Dual-route embedding-aware graph neural networks for drug repositioning.Briefings in bioinformatics · 2025Article
- Cancer network pharmacology: multi-network regulatory mechanisms and future directions.Medical oncology (Northwood, London, England) · 2025Review
- A Deep Learning Decision Support Tool to Improve Risk Stratification and Reduce Unnecessary Biopsies in BI-RADS 4 Mammograms.Radiology. Artificial intelligence · 2023Article
- Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition.ACS pharmacology & translational science · 2023Article
- Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.Journal of cancer research and clinical oncology · 2023Article
- Contexts and contradictions: a roadmap for computational drug repurposing with knowledge inference.Briefings in bioinformatics · 2022Review
- Artificial intelligence unifies knowledge and actions in drug repositioning.Emerging topics in life sciences · 2021Review
- Drug Repositioning and Subgroup Discovery for Precision Medicine Implementation in Triple Negative Breast Cancer.Cancers · 2021Article
- Application of network link prediction in drug discovery.BMC bioinformatics · 2021Article
- A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling.Cell chemical biology · 2019Article
- FunDMDeep-m6A: identification and prioritization of functional differential m6A methylation genes.Bioinformatics (Oxford, England) · 2019Article
- A review of computational drug repurposing.Translational and clinical pharmacology · 2019Review
- An Integrated System Biology Approach Yields Drug Repositioning Candidates for the Treatment of Heart Failure.Frontiers in genetics · 2019Article
- Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma.Science translational medicine · 2018Article
- Changing Trends in Computational Drug Repositioning.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Drug Repositioning for Effective Prostate Cancer Treatment.Frontiers in physiology · 2018Review
- On the Integration ofFrontiers in pharmacology · 2017Article
- Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets.Biomedicines · 2016Review
- A survey of current trends in computational drug repositioning.Briefings in bioinformatics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Little research has been done to address the huge opportunities that may exist to reposition existing approved or generic drugs for alternate uses in cancer therapy. In addition, there has been little work on strategies to reposition experimental cancer agents for testing in alternate settings that could shorten their clinical development time. Progress in each area has lagged, in part, because of the lack of systematic methods to define drug off-target effects (OTE) that might affect important cancer cell signaling pathways. In this study, we addressed this critical gap by developing an OTE-based method to repurpose drugs for cancer therapeutics, based on transcriptional responses made in cells before and after drug treatment. Specifically, we defined a new network component called cancer-signaling bridges (CSB) and integrated it with a Bayesian factor regression model (BFRM) to form a new hybrid method termed CSB-BFRM. Proof-of-concept studies were conducted in breast and prostate cancer cells and in promyelocytic leukemia cells. In each system, CSB-BFRM analysis could accurately predict clinical responses to more than 90% of drugs approved by the U.S. Food and Drug Administration and more than 75% of experimental clinical drugs that were tested. Mechanistic investigation of OTEs for several high-ranking drug-dose pairs suggested repositioning opportunities for cancer therapy, based on the ability to enforce retinoblastoma-dependent repression of important E2F-dependent cell-cycle genes. Together, our findings establish new methods to identify opportunities for drug repositioning or to elucidate the mechanisms of action of repositioned drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.